NCT06822829Recruiting
Multicenter Retrospective Observational Study of Relapsed Diffuse Large B-Cell Lymphoma Presenting as Indolent Lymphoma
Source: ClinicalTrials.gov · Last updated 5 May 2026
Brief summary (registry, in English)
Most relapses of diffuse large B-cell lymphoma (DLBCL) occur as high-grade lymphoma within the first two years after diagnosis. Relapses as indolent lymphoma are rare events, and the true incidence of this phenomenon is unknown, since literature data are scarce/ and usually restricted to case reports. Analogously, reported treatment strategies are rather heterogeneous, since no standard of care is established and advanced age together with previous anthracycline exposure may narrow the therapeutic choice. The goal of this observational study is to assess epidemiological, clinical characteristics and survival of diffuse large b-cell lymphoma (DLBCL) relapsing as indolent lymphoma. More precisely, the study aims at identifying diagnostic and imaging features associated with relapse as indolent lymphoma and at evaluating disease response to selected therapies.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 50 (estimated)
- First submitted
- 7 Feb 2025
- Start date
- 19 Aug 2024
- Primary completion date
- 17 Oct 2025
- Lead sponsor
- Azienda USL Reggio Emilia - IRCCS
- Diseases
- Diffuse large B-cell lymphoma
- NCT number
- NCT06822829
What you commit to
- Study type: Observational
- Planned participants: 50
- From 19 Aug 2024 to the primary completion date, 17 Oct 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- \- None
Who the study is looking for
- Age 18 years or older at the time of diagnosis.
- Previous diagnosis of diffuse large B-cell lymphoma with/without a discordant component of indolent B-cell lymphoma, or previous diagnosis of diffuse large B-cell lymphoma transformed from indolent B-cell lymphoma.
- First-line treatment for diffuse large B-cell lymphoma.
- Histologically documented relapse of indolent B-cell lymphoma, diagnosed between 2010 and 2020.
- Availability of the histological report of the relapse.
- Availability of clinical and laboratory data related to both the initial diagnosis and relapse.
- Availability of follow-up data.
- Consent to participate in the study and signing of the specific informed consent form (for living and/or contactable patients).
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Azienda USL IRCCS di Reggio Emilia Coordinator of this site? Confirm its status | Reggio Emilia | Italy | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.